An AI model can accurately flag EGFR mutations in lung adenocarcinoma using routine pathology slides, reducing the need for rapid genetic tests.
Key Details
- 1Researchers from Mount Sinai, Memorial Sloan Kettering, and collaborators published results in Nature Medicine on July 9, 2025.
- 2The AI model predicts EGFR mutations from H&E-stained pathology slides of lung adenocarcinoma.
- 3A live 'silent trial' at Memorial Sloan Kettering showed the model could reduce rapid genetic testing by over 40%.
- 4The model was trained and validated on the largest multi-institutional dataset of matched slides and sequencing results from the US and Europe.
- 5Preserving tissue by avoiding unnecessary rapid tests allows for more comprehensive genomic sequencing.
- 6Work is ongoing to broaden the model's biomarker detection and deploy it in more healthcare settings.
Why It Matters
This study demonstrates the practical integration of AI in pathology workflows, expediting precision therapy decisions and optimizing tissue usage in lung cancer diagnostics. It signals a major step toward AI-driven personalization in oncology, with potential to improve both efficiency and patient outcomes.
Source
EurekAlert
Related News
•EurekAlert
AI and Advanced Microscopy Unveil Cell's Exocytosis Nanomachine
Researchers have discovered the ExHOS nanomachine responsible for constitutive exocytosis using advanced microscopy and AI-enhanced image analysis.
•EurekAlert
Physical Activity Linked to Breast Tissue Biomarkers in Teens
A study links adolescent recreational physical activity to changes in breast tissue composition and stress biomarkers, potentially impacting future breast cancer risk.
•EurekAlert
AI Reveals Key Health System Levers for Cancer Outcomes Globally
AI-based analysis identifies the most impactful policy and resource factors for improving cancer survival across 185 countries.